The United Kingdom has launched a major clinical trial to determine whether breast cancer radiotherapy can be safely delivered in just five days instead of the conventional three-week treatment period.
More than 1,000 patients are participating in the FAST-Forward Boost trial across 39 hospitals nationwide.
The study, led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, is examining a shortened radiotherapy schedule combined with an additional targeted radiation dose.
Researchers hope the approach will maintain treatment effectiveness while significantly reducing the time patients spend undergoing hospital treatment.
If successful, the new approach could save eligible patients approximately 10 hospital visits, reducing transportation costs and the disruption to their work and family lives.
The trial could mark a significant development in breast cancer treatment, particularly for patients who face difficulties attending frequent hospital appointments.
However, specialists must establish the safety and effectiveness of the five-day treatment before it can become standard practice.
Meanwhile, patients have been advised to continue following their doctors’ recommendations as the clinical trial progresses.
UK Trials Five-Day Breast Cancer Radiotherapy to Cut Hospital Visits
The United Kingdom has launched a major clinical trial to determine whether breast cancer radiotherapy can be safely delivered in just five days instead of the conventional three-week treatment period.
More than 1,000 patients are participating in the FAST-Forward Boost trial across 39 hospitals nationwide.
The study, led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, is examining a shortened radiotherapy schedule combined with an additional targeted radiation dose.
Researchers hope the approach will maintain treatment effectiveness while significantly reducing the time patients spend undergoing hospital treatment.
If successful, the new approach could save eligible patients approximately 10 hospital visits, reducing transportation costs and the disruption to their work and family lives.
The trial could mark a significant development in breast cancer treatment, particularly for patients who face difficulties attending frequent hospital appointments.
However, specialists must establish the safety and effectiveness of the five-day treatment before it can become standard practice.
Meanwhile, patients have been advised to continue following their doctors’ recommendations as the clinical trial progresses.
UK Trials Five-Day Breast Cancer Radiotherapy to Cut Hospital Visits
The United Kingdom has launched a major clinical trial to determine whether breast cancer radiotherapy can be safely delivered in just five days instead of the conventional three-week treatment period.
More than 1,000 patients are participating in the FAST-Forward Boost trial across 39 hospitals nationwide.
The study, led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, is examining a shortened radiotherapy schedule combined with an additional targeted radiation dose.
Researchers hope the approach will maintain treatment effectiveness while significantly reducing the time patients spend undergoing hospital treatment.
If successful, the new approach could save eligible patients approximately 10 hospital visits, reducing transportation costs and the disruption to their work and family lives.
The trial could mark a significant development in breast cancer treatment, particularly for patients who face difficulties attending frequent hospital appointments.
However, specialists must establish the safety and effectiveness of the five-day treatment before it can become standard practice.
Meanwhile, patients have been advised to continue following their doctors’ recommendations as the clinical trial progresses.
